Pharmaceutical Business review

Biostar files PRC patent application for oleanolic acid injection for hepatitis B and liver cancer

The application passed the preliminary examination of the PRC State Intellectual Property Bureau and was accepted for review; the application acceptance number is 201410182757.7.

The filed patent is for the pharmaceutical and preparation method developed by the Company’s R&D team, together with the experts of Shaanxi University of Chinese Medicine after nearly 2 years of research and development effort.

It is one of drug development efforts by the Company in combating Hepatitis B and liver cancer and is currently under pharmacological research.

Mr. Ronghua Wang, Chairman of the Company commented: "The filing and acceptance for review of the invention patent application indicates that the Company had made considerable progress in developing its Oleanolic Acid Injection. This promises to establish technical foundation for the product’s research and development and future expansion. The Company will continue to increase investment in its research and development efforts to generate effective drugs for the PRC markets."